

Neurotech

30 November 2020

Results of Annual General Meeting

Neurotech International Limited (ASX:NTI) ('NTI' or 'the Company') today held an Annual General Meeting of Members at the offices of Azalea Consulting Pty Ltd, Suite 5, 145 Stirling Highway, Nedlands WA 6009.

All resolutions were determined by a poll.

The outcome of each resolution put to shareholders at the Annual General Meeting is set out in the Annexure which accompanies this release.

Authority

This announcement has been authorised for release by Winton Willesee, Director.

Further Information

Erlyn Dale
Company Secretary
erlyn@azc.com.au
+61 424 676 671

Winton Willesee
Non-Executive Director
winton@azc.com.au
+61 410 667 844

About Neurotech

Neurotech International Limited is a medicinal cannabis company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary DOLCE/NTI cannabis strains which include CBDA, CBDP and CBDB. The licensed strains contain < 0.3% THC providing a clearer pathway to regulatory approval as compared to all other cannabis companies that contain far higher levels of THC. Neurotech is also commercialising *Mente*, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and *Mente* Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Neurotech International Ltd

ABN 73 610 205 402

Suite 5 CPC, 145 Stirling Highway
Nedlands, Western Australia 6009

www.neurotechinternational.com

Disclosure of Proxy Votes

NEUROTECH INTERNATIONAL LIMITED

Annual General Meeting

Monday, 30 November 2020



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of the Remuneration Report	P	46,157,817	45,856,678 99.35%	293,839 0.64%	5,370,436	7,300 0.02%	46,136,708 99.37%	293,839 0.63%	5,370,436
2 Re-election of Mr Winton Willesee as a Director	P	59,321,270	59,026,131 99.50%	277,839 0.47%	0	17,300 0.03%	59,316,161 99.53%	277,839 0.47%	0
3 Re-election of Mr Brian Leedman as a Director	P	59,321,270	59,026,131 99.50%	277,839 0.47%	0	17,300 0.03%	59,316,161 99.53%	277,839 0.47%	0
4 Approval to issue Shares to Dolce Cann Global Pty Ltd	P	59,043,270	58,748,131 99.50%	277,839 0.47%	278,000	17,300 0.03%	59,038,161 99.53%	277,839 0.47%	278,000
5(a) Approval to issue Options to Directors – Mr Winton Willesee	P	54,138,834	53,843,695 99.45%	277,839 0.51%	5,182,436	17,300 0.03%	54,133,725 99.49%	277,839 0.51%	5,182,436
5(b) Approval to issue Options to Directors – Mr Mark Davies	P	51,478,253	51,183,114 99.43%	277,839 0.54%	7,843,017	17,300 0.03%	51,473,144 99.46%	277,839 0.54%	7,843,017
6(a) Approval to Issue Options to Director – Brian Leedman	P	59,321,270	59,026,131 99.50%	277,839 0.47%	0	17,300 0.03%	59,316,161 99.53%	277,839 0.47%	0



Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
6(b) Approval to Issue Options to Director – Brian Leedman	P	59,271,270	58,976,131 99.50%	277,839 0.47%	50,000	17,300 0.03%	59,266,161 99.53%	277,839 0.47%	50,000
7 Approval of Additional 10% Placement Facility	P	59,321,270	58,761,231 99.06%	542,739 0.91%	0	17,300 0.03%	59,051,261 99.09%	542,739 0.91%	0

